Inventor · disambiguated record
Christian Lange
Also filed as: LANGE CHRISTIAN
24 granted patents·27 pending applications·143 citations·filing 2001–2024
95Inventor score
Top patents by PatentIndex Score
51 records- 0196US11192960B2Trispecific and/or trivalent binding proteinsSANOFI SA·Filed 2020·Granted Dec 7, 2021·6 cites·30 claims
- 0296US10882922B2Trispecific and/or trivalent binding proteinsSANOFI SA·Filed 2017·Granted Jan 5, 2021·20 cites·47 claims
- 0395US11779651B2Bivalent, bispecific binding proteins for prevention or treatment of HIV infectionSANOFI SA·Filed 2021·Granted Oct 10, 2023·2 cites·3 claims
- 0494US9221917B2Dual variable region antibody-like binding proteins having cross-over binding region orientationBAURIN NICOLAS·Filed 2013·Granted Dec 29, 2015·23 cites·21 claims
- 0594US9181349B2Dual variable region antibody-like binding proteins having cross-over binding region orientationBAURIN NICOLAS·Filed 2013·Granted Nov 10, 2015·29 cites·26 claims
- 0693US11129905B2Bivalent, bispecific binding proteins for prevention or treatment of HIV infectionSANOFI SA·Filed 2019·Granted Sep 28, 2021·6 cites·3 claims
- 0789US7629456B2Modified L-nucleic acidNOXXON PHARMA AG·Filed 2002·Granted Dec 8, 2009·31 cites·20 claims
- 0886US2025312475A1Bivalent, bispecific binding proteins for prevention or treatment of hiv infectionSANOFI SA·Filed 2024·Application pending·0 cites
- 0984US10626169B2Multispecific binding molecules having specificity to dystroglycan and laminin-2SANOFI SA·Filed 2018·Granted Apr 21, 2020·8 cites·17 claims
- 1083US8852593B2Antagonist antibodies and their fab fragments against GPVI and uses thereofBAURIN NICOLAS·Filed 2010·Granted Oct 7, 2014·8 cites·8 claims
- 1182US12054552B2Humanized anti-IL-1R3 antibody and methods of useSANOFI BIOTECHNOLOGY·Filed 2023·Granted Aug 6, 2024·1 cites·22 claims
- 1278US11820809B2Multispecific antibodies facilitating selective light chain pairingSANOFI SA·Filed 2017·Granted Nov 21, 2023·2 cites·14 claims
- 1376US10906978B2Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123SANOFI SA·Filed 2018·Granted Feb 2, 2021·1 cites·22 claims
- 1475US10947284B2Fusion moleculesPIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Mar 16, 2021·1 cites·22 claims
- 1575US10316071B2Fusion moleculesSANOFI SA·Filed 2016·Granted Jun 11, 2019·2 cites·15 claims
- 1674US2024279362A1Trispecific and/or trivalent binding proteinsSANOFI SA·Filed 2024·Application pending·0 cites
- 1773US2021189011A1Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region OrientationSANOFI SA·Filed 2020·Application pending·0 cites
- 1871US11965030B2Multispecific binding proteins with mutant fab domainsSANOFI SA·Filed 2019·Granted Apr 23, 2024·1 cites·15 claims
- 1971US2025115669A1FGFR1/KLB Targeting Agonistic Antigen-Binding Proteins and Conjugates Thereof with GLP-1R Agonistic PeptidesSANOFI SA·Filed 2024·Application pending·0 cites
- 2067US2020010833A1Modified L-Nucleic AcidNOXXON PHARMA AG·Filed 2019·Application pending·0 cites
- 2167US2010081710A1Modified L-Nucleic AcidNOXXON PHARMA AG·Filed 2009·Application pending·0 cites
- 2266US11932704B2Trispecific and/or trivalent binding proteinsSANOFI SA·Filed 2021·Granted Mar 19, 2024·0 cites·7 claims
- 2366US7297535B2Use of the human LRP/MVP promotor for a vector that can be induced by therapyMAX DELBRUECK CENTRUM·Filed 2001·Granted Nov 20, 2007·1 cites·7 claims
- 2466US2023391888A1Pseudofab-based multispecific binding proteinsSANOFI SA·Filed 2023·Application pending·0 cites
- 2565US2025019452A1Humanized anti-il-1r3 antibody and methods of useSANOFI BIOTECHNOLOGY·Filed 2024·Application pending·0 cites
- 2665US2018155450A1Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region OrientationSANOFI SA·Filed 2017·Application pending·0 cites
- 2764US2010062436A1Methods for Detection of a Single- or Double-Stranded Nucleic Acid MoleculeNOXXON PHARMA AG·Filed 2007·Application pending·0 cites
- 2863US2015038562A1Modified L-nucleic AcidNOXXON PHARMA AG·Filed 2014·Application pending·0 cites
- 2963US2021292423A1Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123SANOFI SA·Filed 2021·Application pending·0 cites
- 3063US2018179541A1Modified L-Nucleic AcidNOXXON PHARMA AG·Filed 2018·Application pending·0 cites
- 3161US12054551B2FGFR1/KLB targeting agonistic antigen-binding proteins and conjugates thereof with GLP-1R agonistic peptidesSANOFI SA·Filed 2021·Granted Aug 6, 2024·0 cites·14 claims
- 3261US11739160B2PseudoFab-based multispecific binding proteinsSANOFI SA·Filed 2019·Granted Aug 29, 2023·0 cites·36 claims
- 3360US9234039B2Peptide or peptide complex binding to ALPHA2 integrin and methods and uses involving the sameCORVEY CARSTEN·Filed 2011·Granted Jan 12, 2016·1 cites·17 claims
- 3460US2016200811A1Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region OrientationSANOFI SA·Filed 2015·Application pending·0 cites
- 3560US2012251541A1Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region OrientationBAURIN NICOLAS·Filed 2012·Application pending·0 cites
- 3658US2016376594A1Modified L-Nucleic AcidNOXXON PHARMA AG·Filed 2016·Application pending·0 cites
- 3757US9441040B2Antagonist antibodies and their fab fragments against GPVI and uses thereofSANOFI SA·Filed 2014·Granted Sep 13, 2016·0 cites·15 claims
- 3857US2019054182A1Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infectionSANOFI SA·Filed 2016·Application pending·0 cites
- 3956US2012214868A1Modified L-Nucleic AcidLANGE CHRISTIAN·Filed 2012·Application pending·0 cites
- 4055US2012258457A1Methods for Detection of a Single- or Double-Stranded Nucleic Acid MoleculeJAROSCH FLORIAN·Filed 2012·Application pending·0 cites
- 4154US2024043522A1Effectorless fc moleculesSANOFI SA·Filed 2021·Application pending·0 cites
- 4253US2023103563A1Split ch2 domainsSANOFI SA·Filed 2021·Application pending·0 cites
- 4346US2018057597A1Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123SANOFI SA·Filed 2017·Application pending·0 cites
- 4445US11254737B2Multispecific binding molecules having specificity to dystroglycan and laminin-2SANOFI SA·Filed 2020·Granted Feb 22, 2022·0 cites·38 claims
- 4545US9989524B2Immuno imaging agent for use with antibody-drug conjugate therapySANOFI SA·Filed 2014·Granted Jun 5, 2018·0 cites·22 claims
- 4644US9844607B2Immuno imaging agent for use with antibody-drug conjugate therapySANOFI SA·Filed 2014·Granted Dec 19, 2017·0 cites·12 claims
- 4740US2016176970A1Peptide or peptide complex binding to alpha2 integrin and methods and uses involving the sameSANOFI SA·Filed 2015·Application pending·0 cites
- 4838US2015183846A1Human fusion proteins comprising single chain tnfalpha and targeting domainsSCIL PROTEINS GMBH·Filed 2013·Application pending·0 cites
- 4936US2019241657A1Bispecific antibody-like binding proteins specifically binding to cd3 and cd123SANOFI SA·Filed 2017·Application pending·0 cites
- 5035US2014219959A1Human fusion proteins comprising interferons and targeted modified ubiquitin proteinsNERKAMP JOERG·Filed 2012·Application pending·0 cites
Showing the top 50 of 51 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Christian Lange files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →